ReNAgade Therapeutics

Acquisition, funding and merger involving ReNAgade Therapeutics.

• ReNAgade Therapeutics has just announced a $300 Million fundraising (posted on May 25 2023).

View the org chart displaying its 23 main executives

Most searched biographies at ReNAgade Therapeutics

• Amit Munshi, Chief Executive Officer and Chairman of the Board
• Matt Roden, Director
• Ansbert Gadicke, Director

Popular executive movements at ReNAgade Therapeutics

• Joe Bolen has joined the company as Chief Science Innovation Officer  (posted on February 28 2024).
• Paul Perreault has joined the company as Director  (posted on December 6 2023).
• Laurie Stelzer has joined the company as Chief Financial Officer  (posted on September 13 2023).

Create your alert
to follow the executive moves at ReNAgade Therapeutics.

ReNAgade Therapeutics has 1,819 competitors including Siemens Healthineers (Germany), IQVIA (United States (USA)) and Saint Francis Health System (United States (USA)).

Popular M&A news in Healthcare

• Midi Health has just announced a $60 Million fundraising (posted on April 29 2024).
• Xaira Therapeutics becomes a unicorn with its fundraising of $1,000 Million. (posted on April 25 2024).
• Two Chairs has just announced a $72 Million fundraising (posted on April 18 2024).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Bryan Roberts - Director at Included Health
• Sima Sistani - Chief Executive Officer and Director at WW International

Learn more about the Healthcare industry >

Press releases by ReNAgade Therapeutics

• ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
• ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
• Evercore ISI 2024 Emerging Biotech Conference Webcast
• ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
• ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors
• ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference
• ReNAgade Therapeutics Named to the 2023 Endpoints 11
• ReNAgade Therapeutics Launches with Over $300 Million in Series A Financing to Unlock the Limitless Potential of RNA Medicine
• News
• ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
• View more press releases Close

Social media about ReNAgade Therapeutics

• ReNAgade Therapeutics on Wikipedia, Google News & Yahoo Finance
• ReNAgade Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Morana Jovan-Embiricos

Call ReNAgade Therapeutics at +1 617...

View the org chart

Register to receive your alert

Report an error